Léčba idelalisibem u pacienta s nežádoucím účinky ibrutinibu
| Title in English | Treatment of patient with Idealisib due to side effects of Ibrutinib |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Popularization text |
| MU Faculty or unit | |
| Citation | |
| Attached files | |
| Description | The prognosis of relapsed form of chronic lymfocytic leukemia is poor. This case study describes a patient with CLL, who is treated with several lines of therapy. In the 5th line of the treatment one of the new inhibitor of BCR signaling pathway is administered - Ibrutinib. Although it leads to induce partial remission, a hemorrhage very frequent side effect appears. Therefore other BCR signaling inhibitor is used - inhibitor PI3K Idealisib - which finally provides better long-term therapeutic effects. |